MYC‑driven tumors silence innate immune alarms by clearing R‑loop–derived signals, exposing a new therapeutic angle for targeting MYC without broad inhibition.

A team at Johns Hopkins Medicine has focused their work on myelin development using oligodendrocytes to help study conditions like MS.

Chai Discovery, Noetik, and Boltz have entered multi-year pharma partnerships focused on models, not molecules, hinting at AI’s “infrastructure moment.” ...